HK2 and plasma cell myeloma: LDHA is associated with breast cancer resistance to paclitaxel/trastuzumab and myeloma relapse (Zhao et al., 2011); overexpression of hexokinase 2 (HK2) is involved in cisplatin resistance in ovarian cancer cells, by enhancing autophagy (Zhang et al., 2018) and the increased expression of PDK2 is linked to paclitaxel resistance in NSCLC (Sun et al., 2017).